|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Tumor Biology |
The Hermelin Brain Tumor Center (S.V.V., S.A.R.), Josephine Ford Cancer Center (J.M., A.N.), and the Department of Biostatistics and Epidemiology (S.S.S., G.D.), Henry Ford Hospital, Detroit, MI 48202, USA
2 Address correspondence to Sandra A. Rempel, Barbara Jane Levy Laboratory of Molecular Neuro-Oncology, Hermelin Brain Tumor Center, Department of Neurosurgery, Room 3096, Education and Research Building, Henry Ford Hospital, 2799 West Grand Blvd., Detroit, MI 48202 (nssan{at}neuro.hfh.edu).
Abstract
Secreted protein acidic and rich in cysteine (SPARC) has a suppressive effect on U87 glioma cell proliferation when assessed in vitro and in vivo using parental U87T2 and U87T2-derived SPARC-transfected clones. Since SPARC interacts with extracellular matrix (ECM) proteins, we examined the effect of SPARC secretion on proliferation, morphology, and cell density of glioma cells grown in vitro, in the absence and presence of ECM proteins under standard (10% fetal bovine serum [FBS]) and reduced (0.1% FBS) serum stress conditions. Under standard conditions, MTT (3-(4,5-cimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide) growth curves, morphology, and Western blot analyses demonstrated that SPARC had a suppressive and biphasic effect on growth that was not grossly modulated by the ECMs. The SPARC-induced changes in morphology observed at 24 h were not altered by the presence of ECMs. Under reduced-serum stress conditions, Western blot, morphological, and flow cytometric analyses indicated that the SPARC-induced suppressive growth effects were eliminated when the cells were grown on plastic. However, ECM-specific changes in growth were observed, some of which correlated with secreted SPARC levels. These results indicate that the differential effects of SPARC and ECMs on proliferation are dependent on culture conditions. Since the results obtained under standard conditions agree with our in vivo observations, we conclude that the ability of SPARC to suppress proliferation is regulated to a greater degree by the level of SPARC and that this suppressive effect is not influenced by the presence of any of the ECMs examined.
References
Akiyama, Y., Jung, S., Salhia, B., Lee, S., Hubbard, S., Taylor, M., Mainprize, T., Akaishi, K., van Furth, W., and Rutka, J.T. (2001) Hyaluronate receptors mediating glioma cell migration and proliferation. J. Neurooncol. 53,115 -127.[CrossRef][Medline]
Axisa, B., Loftus, I.M., Naylor, A.R., Goodall, S., Jones, L.,
Bell, P.R., and Thompson, M.M. (2002) Prospective, randomized,
double-blind trial investigating the effect of doxycycline on matrix
metalloproteinase expression within atherosclerotic carotid plaques.
Stroke 33,2858
-2864.
Bornstein, P., and Sage, E.H. (2002) Matricellular proteins: Extracellular modulators of cell function. Curr. Opin. Cell Biol. 14,608 -616.[CrossRef][Web of Science][Medline]
Bradshaw, A.D., Francki, A., Motamed, K., Howe, C., and Sage, E.H.
(1999) Primary mesenchymal cells isolated from SPARC-null mice
exhibit altered morphology and rates of proliferation. Mol. Biol.
Cell 10,1569
-1579.
Funk, S.E., and Sage, E.H. (1991) The
Ca2+-binding glycoprotein SPARC modulates cell cycle progression in
bovine aortic endothelial cells. Proc. Natl. Acad. Sci.
USA 88,2648
-2652.
Funk, S.E., and Sage, E.H. (1993) Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J. Cell. Physiol. 154, 53-63.[CrossRef][Web of Science][Medline]
Gladson, C.L. (1999) The extracellular matrix of gliomas: Modulation of cell function. J. Neuropathol. Exp. Neurol. 58,1029 -1040.[Web of Science][Medline]
Golembieski, W.A., and Rempel, S.A. (2002) cDNA array analysis of SPARC-modulated changes in glioma gene expression. J. Neurooncol. 60,213 -226.[CrossRef][Medline]
Golembieski, W.A., Ge, S., Nelson, K., Mikkelsen, T., and Rempel, S.A. (1999) Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int. J. Dev. Neurosci. 17,463 -472.[CrossRef][Web of Science][Medline]
Greenwood, J.A., and Murphy-Ullrich, J.E. (1998) Signaling of de-adhesion in cellular regulation and motility. Microsc. Res. Tech. 43,420 -432.[CrossRef][Web of Science][Medline]
Hasselaar, P., and Sage, E.H. (1992) SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell. Biochem. 49,272 -283.[CrossRef][Web of Science][Medline]
Kamihagi, K., Katayama, M., Ouchi, R., and Kato, I. (1994) Osteonectin/SPARC regulates cellular secretion rates of fibronectin and laminin extracellular matrix proteins. Biochem. Biophys. Res. Commun. 200,423 -428.[CrossRef][Web of Science][Medline]
Kupprion, C., Motamed, K., and Sage E.H. (1998) SPARC
(BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial
growth factor on microvascular endothelial cells. J. Biol.
Chem. 273,29635
-29640.
Lamparter, S., Slight, S.H., and Weber, K.T. (2002) Doxycycline and tissue repair in rats. J. Lab. Clin. Med. 139,295 -302.[CrossRef][Web of Science][Medline]
Lane, T.F., Iruela-Arispe, M.L., and Sage, E.H. (1992)
Regulation of gene expression by SPARC during angiogenesis in vitro.
Changes in fibronectin, thrombospondin-1, and plasminogen activator
inhibitor-1. J. Biol. Chem.
267,16736
-16745.
Mayer, U., Aumailley, M., Mann, K., Timpl, R., and Engel, J. (1991) Calcium-dependent binding of basement membrane protein BM-40 (osteonectin, SPARC) to basement membrane collagen type IV. Eur. J. Biochem. 198,141 -150.[Web of Science][Medline]
Menon, P.M., Gutierrez, J.A., and Rempel, S.A. (2000) A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: High SPARC secretion correlates with decreased migration on vitronectin. Int. J. Oncol. 17,683 -693.[Web of Science][Medline]
Murphy-Ullrich, J.E. (2001) The de-adhesive activity of matricellular proteins: Is intermediate cell adhesion an adaptive state? J. Clin. Invest. 107,785 -790.[CrossRef][Web of Science][Medline]
NIH. National Institutes of Health. (2003) NIH Image. Available at http://rsb.info.nih.gov/nih-image/about.html, accessed June 27, 2003.
Pichler, R.H., Bassuk, J.A., Hugo, C., Reed, M.J., Eng, E., Gordon, K.L., Pippin, J., Alpers, C.E., Couser, W.G., Sage, E.H., and Johnson, R.J. (1996) SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-mediated mesangial cell proliferation in vitro. Am. J. Pathol. 148,1153 -1167.[Abstract]
Raines, E.W., Lane, T.F., Iruele-Arispe, M.L., Ross, R., and Sage,
E.H. (1992) The extracellular glycoprotein SPARC interacts with
platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of
PDGF to its receptors. Proc. Natl. Acad. Sci. USA
89,1281
-1285.
Rempel, S.A., Golembieski, W.A., Ge, S., Lemke, N., Elisevich, K., Mikkelsen, T., and Gutiérrez, J.A. (1998) SPARC: A signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J. Neuropathol. Exp. Neurol. 57,1112 -1121.[Web of Science][Medline]
Rempel, S.A., Golembieski, W.A., Fisher, J.L., Maile, M., and Nakeff, A. (2001) SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J. Neurooncol. 53,149 -160.[CrossRef][Medline]
Rosenblatt, S., Bassuk, J.A., Alpers, C.E., Sage, E.H., Timpl, R., and Preissner, K.T. (1997) Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: Characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem. J. 324,311 -319.
Sage, E.H., and Bornstein, P. (1991) Extracellular
proteins that modulate cell-matrix interactions. SPARC, tenascin, and
thrombospondin. J. Biol. Chem.
266,14831
-14834.
Sage, E.H., Bassuk, J.A., Yost, J.C., Folkman M.J., and Lane, T.F. (1995) Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca2+-binding EF-hand sequence. J. Cell Biochem. 57,127 -140.[CrossRef][Web of Science][Medline]
Sasaki, T., Gohring, W., Mann, K., Maurer, P., Hohenester, E.,
Knauper, V., Murphy, G., and Timpl, R. (1997) Limited cleavage of
extracellular matrix protein BM-40 by matrix metalloproteinases increases its
affinity for collagens. J. Biol. Chem.
272,9237
-9243.
Schultz, C., Lemke, N., Ge, S., Golembieski, W.A., and Rempel S.A.
(2002) Secreted protein acidic and rich in cysteine promotes
glioma invasion and delays tumor growth in vivo. Cancer
Res. 62,6270
-6277.
Uitto, V.J., Firth, J.D., Nip, L., and Golub, L.M. (1994). Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann. N.Y. Acad. Sci. 732,140 -151.[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Wang, C. Mei, B. Tang, H. Zhao, C. Xu, Z. Li, X. Shen, W. Fu, and B. Dai Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1278 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation J. Biol. Chem., December 10, 2004; 279(50): 52200 - 52209. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
